The goal of Falcon Genomics, Inc. is to personalize the treatment of cancer.
Falcon Genomics' technology platform, the Cancer BioChip System (CBCS™) identifies the specific genes responsible for cancer cell growth. The CBCS™ contains over 30,000 specific inhibitors, based on silencing RNA (siRNA), for every possible combination of genes that could be abnormally expressed. By eliminating the tedious trial and error associated with current cancer treatments, the CBCS™ will vastly accelerate the identification of precise and tailored treatment strategies.
The CBCS™ can be used for both patient-specific cancer diagnosis, and for high-throughput screening of cancer therapeutic targets.
As compared to current technology for treating cancer, our technology casts a wide net to provide specific and rapid results. It is analogous to a falcon swooping on its prey at a speed of 100 mph.